A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.

Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.

Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).

A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030).

Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma

Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses.

Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma.

Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.

Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma.

Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.